ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Final Issues Of 1982

December 10, 1982

CIRC Attempting To Write Guidelines For Budget Review Of Cooperative Groups

March 6, 1981

Hugh Creech, Fox Chase Chemotherapy Pioneer, Dead at 92

January 31, 2003

Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show

November 28, 1986

Judge Sentences Former BMS Exec Bodner To Write Book Reflecting On His Experience

June 12, 2009

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001